Publications by authors named "H H Mansbach"
Article Synopsis
- A clinical study evaluated the effects of pegozafermin, a new therapy, on patients with nonalcoholic steatohepatitis (NASH) and fibrosis to meet an important medical need.
- The study involved adults with specific criteria receiving weekly doses for 20 weeks, measuring improvements in liver condition and safety.
- Results showed significant improvements in liver health and metabolic factors, with most participants tolerating the treatment well, although some experienced mild adverse effects.
Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. In a phase Ib/IIa placebo-controlled, double-blind, multiple ascending dose study in patients with NASH (NCT04048135), administration of pegozafermin resulted in clinically meaningful reductions in hepatic fat fraction (HFF), with a favorable safety and tolerability profile. We aimed to characterize the relationship between pegozafermin dosing, exposure and effects on HFF reduction.
View Article and Find Full Text PDF